The Mechanism of DAB2IP in Chemoresistance of Prostate Cancer Cells
- 1 September 2013
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 19 (17), 4740-4749
- https://doi.org/10.1158/1078-0432.ccr-13-0954
Abstract
Purpose: The docetaxel-based chemotherapy is the standard of care for castration-resistant prostate cancer (CRPC), inevitably, patients develop resistance and decease. Until now, the mechanism and predictive marker for chemoresistance are poorly understood. Experimental Design: Immortalized normal prostate and cancer cell lines stably manipulated with different DAB2IP expression levels were used and treated with chemotherapeutic drugs commonly used in prostate cancer therapy. Cell proliferation was measured using MTT assay; Western blot, quantitative PCR, and luciferase reporter assays were used to analyze Clusterin gene regulation by DAB2IP. Immunohistochemical analysis was conducted for evaluating DAB2IP, Clusterin and Egr-1 expression in human prostate cancer tissue. Results: DAB2IP Knockdown (KD) cells exhibited resistance to several chemotherapeutic drugs, whereas increased DAB2IP in C4-2 cells restored the drug sensitivity. Parallel, DAB2IP KD cells exhibited higher expression of Clusterin, an antiapoptotic factor, whereas elevated DAB2IP in C4-2 cells decreased Clusterin expression. Functionally, knocking down Clusterin by short-hairpin RNA or antisense oligonucleotide OGX-011 decreased drug resistance, whereas overexpressing Clusterin in C4-2 D2 enhanced drug resistance. Mechanistically, DAB2IP blocked the cross-talk between Wnt/β-catenin and IGF-I signaling, leading to the suppression of Egr-1 that is responsible for Clusterin expression. A similar result was observed in the prostate of DAB2IP knockout animals. In addition, we observed a significantly inverse correlation between DAB2IP and Egr-1 or Clusterin expression from clinical tissue microarray. Conclusions: This study unveils a new regulation of the Egr-1/Clusterin signaling network by DAB2IP. Loss of DAB2IP expression in CRPC cells signifies their chemoresistance. Clusterin is a key target for developing more effective CRPC therapy. Clin Cancer Res; 19(17); 4740–9. ©2013 AACR.Keywords
Other Versions
This publication has 41 references indexed in Scilit:
- Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate CancerCancer Research, 2011
- Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate CancerCancer Research, 2010
- Targeting the Cytoprotective Chaperone, Clusterin, for Treatment of Advanced CancerClinical Cancer Research, 2010
- An oncogene–tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κBNature Medicine, 2010
- Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasisProceedings of the National Academy of Sciences, 2010
- DAB2IP coordinates both PI3K-Akt and ASK1 pathways for cell survival and apoptosisProceedings of the National Academy of Sciences, 2009
- Is EGR1 a Potential Target for Prostate Cancer Therapy?Future Oncology, 2009
- Advances and Challenges in Basic and Translational Research on ClusterinCancer Research, 2009
- AIP1 functions as an endogenous inhibitor of VEGFR2-mediated signaling and inflammatory angiogenesis in miceJCI Insight, 2008
- Activation of the Wnt Pathway Interferes with Serum Response Element-driven Transcription of Immediate Early GenesPublished by Elsevier BV ,2002